Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)
Close on Nov 17, 2026Market cap $122.22MP/E –Yield –
Fate Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Fate Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$101.91M. For fiscal 2025 it was -$106.08M. The highest annual figure on record is -$12.15M in fiscal 2011.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$106.08M | – |
| FY2024 | Dec 31, 2024 | -$122.87M | – |
| FY2023 | Dec 31, 2023 | -$132.26M | – |
| FY2022 | Dec 31, 2022 | -$248.21M | – |
| FY2021 | Dec 31, 2021 | -$162.87M | – |
| FY2020 | Dec 31, 2020 | -$39.23M | – |
| FY2019 | Dec 31, 2019 | -$83.18M | – |
| FY2018 | Dec 31, 2018 | -$38.65M | – |
| FY2017 | Dec 31, 2017 | -$36.82M | – |
| FY2016 | Dec 31, 2016 | -$29.82M | – |
| FY2015 | Dec 31, 2015 | -$18.40M | – |
| FY2014 | Dec 31, 2014 | -$22.42M | – |
| FY2013 | Dec 31, 2013 | -$15.37M | – |
| FY2012 | Dec 31, 2012 | -$13.27M | – |
| FY2011 | Dec 31, 2011 | -$12.15M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.82M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$36.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$75.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$55.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$64.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$70.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.11M | -182.7% |
| Q1 FY2021 | Mar 31, 2021 | -$27.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.73M | – |
| Q2 FY2020 | Jun 30, 2020 | $38.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.54M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.84M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.31M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.56M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.55M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.77M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.87M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.46M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.52M | – |
See a number that looks wrong?